GURU.Markets stock price, segment price, and overall market index valuation
The company's share price T2 Biosystems Inc.
T2 Biosystems has developed a platform for rapid sepsis diagnostics. Its stock price reflects its long struggle to widely adopt this technology in hospitals. The chart is the story of an innovation facing a slow sales cycle in medicine.
Share prices of companies in the market segment - Diagnostic medical equipment
T2 Biosystems has developed the T2Dx diagnostic platform for the rapid detection of sepsis-causing pathogens directly in whole blood. We have classified it as "Diagnostic Medical Equipment." The chart below shows how the market evaluates sepsis-fighting technologies.
Broad Market Index - GURU.Markets
T2 Biosystems is a company that has developed a platform for rapid diagnosis of sepsis and other dangerous infections directly from a blood sample. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with T2's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
TTOO - Daily change in the company's share price T2 Biosystems Inc.
The daily price change of T2 Biosystems, Inc., a sepsis diagnostics company, reflects volatility in the MedTech sector. The indicator demonstrates sensitivity to sales of its systems and regulatory announcements.
Daily change in the price of a set of shares in a market segment - Diagnostic medical equipment
T2 Biosystems develops diagnostic tests for the rapid detection of sepsis and other dangerous infections. The rapid diagnostics market is competitive and innovative. The chart below shows the volatility in this niche, allowing you to compare TTOO's performance with other companies.
Daily change in the price of a broad market stock, index - GURU.Markets
T2 Biosystems produces systems for the rapid diagnosis of sepsis and other dangerous infections. This medtech company's stock reflects the growing problem of antibiotic resistance. Its price movement reflects the contribution of innovative medicine to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization T2 Biosystems Inc.
T2 Biosystems, Inc.'s year-over-year performance is the story of its struggle to gain adoption for its rapid sepsis diagnostic platform. Its market cap change over the past 12 months reflects its success (or failure) in deploying its devices to hospitals. Its valuation is a bet that its technology, which enables rapid pathogen detection, will become the standard.
Annual dynamics of market capitalization of the market segment - Diagnostic medical equipment
T2 Biosystems is a diagnostics company that has developed a technology for rapid sepsis detection. This chart shows how its innovative technology, the struggle for widespread adoption in hospitals, and competition are impacting its volatile performance in the medical device sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
T2 Biosystems, with its sepsis tests, demonstrates the dynamism of how difficult it is to innovate in medicine. Its ability to stay ahead of the market depends on convincing hospitals of the need for its rapid, but expensive, diagnostics. This is a long road to changing treatment standards.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization T2 Biosystems Inc.
T2 Biosystems is a molecular diagnostics company specializing in sepsis. Its monthly performance reflects the pace of hospital adoption of its T2Dx platform. Quarterly sales reports for systems and consumables are key.
Monthly dynamics of market capitalization of the market segment - Diagnostic medical equipment
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly from whole blood. The graph below illustrates the dynamics of the diagnostics sector, where rapid infection detection can save a patient's life.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
T2 Biosystems is developing a system for the rapid diagnosis of sepsis and other infections. As a medical device company, its growth depends on the adoption of its technology in hospitals. Share price performance is driven by the speed of commercialization, not by general market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization T2 Biosystems Inc.
Shares of T2 Biosystems, a diagnostics company, reflect the fight against sepsis on a weekly basis. The price movement reflects the introduction of their tests for rapid pathogen identification in hospitals, which can save lives, and the company's financial health.
Weekly dynamics of market capitalization of the market segment - Diagnostic medical equipment
T2 Biosystems has developed a technology for the rapid diagnosis of sepsis and other infections. This chart compares its weekly performance with the sector and helps understand how the market views its T2MR technology, given the need for rapid and accurate diagnostics to save lives.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
T2 Biosystems is a company in the medical diagnostics sector. Shares of such companies may be less dependent on general economic cycles. This chart will help us understand whether T2 shares are stuck in a world of clinical trials and the introduction of new tests, or whether the overall market environment still influences their stock price.
Market capitalization of the company, segment and market as a whole
TTOO - Market capitalization of the company T2 Biosystems Inc.
T2 Biosystems' market capitalization tells the story of a company developing rapid diagnostic tests for sepsis. Its volatile price action at low levels reflects its struggle to survive and commercialize its technology. Its dynamics reflect the market's assessment of its chances of its tests becoming standard in hospitals.
TTOO - Share of the company's market capitalization T2 Biosystems Inc. within the market segment - Diagnostic medical equipment
T2 Biosystems is developing technology for the rapid diagnosis of sepsis and other infections. Its small market share reflects both its innovation and the challenges of implementation. The chart below shows how the market perceives its potential to change diagnostic standards in critical care.
Market capitalization of the market segment - Diagnostic medical equipment
T2 Biosystems is a company that has developed technology for the rapid diagnosis of sepsis and other dangerous infections. The chart below shows the market capitalization of this sector. Its dynamics reflect the critical need to speed up diagnostics to save lives, as well as the challenges of widespread adoption of new technologies in hospitals.
Market capitalization of all companies included in a broad market index - GURU.Markets
T2 Biosystems has developed technology for the rapid diagnosis of sepsis and other dangerous infections. Its market cap reflects the belief that speed in diagnostics can save lives. Its volatile performance on the overall chart tells the story of how an innovative medical technology struggles for recognition and market share.
Book value capitalization of the company, segment and market as a whole
TTOO - Book value capitalization of the company T2 Biosystems Inc.
T2 Biosystems' foundation is its capital and magnetic resonance imaging technology for the rapid diagnosis of sepsis and other dangerous infections. This is real, science-intensive capital for saving lives in intensive care units. How has this innovative, yet problematic, diagnostic asset evolved? The chart below tells its story.
TTOO - Share of the company's book capitalization T2 Biosystems Inc. within the market segment - Diagnostic medical equipment
T2 Biosystems has developed a technology for rapid sepsis diagnostics. The chart shows the proportion of its R&D and manufacturing assets, reflecting the physical scale behind its unique diagnostic platform.
Market segment balance sheet capitalization - Diagnostic medical equipment
T2, a molecular diagnostics company, has a moderately capital-intensive business. It requires R&D and manufacturing capabilities for its tests. The BCap_Seg chart for the medical equipment sector shows that innovation requires a material base.
Book value of all companies included in the broad market index - GURU.Markets
T2 Biosystems' assets include its T2Dx technology and diagnostic devices, which rapidly identify sepsis pathogens directly from whole blood. The balance sheet reflects its patents and manufacturing capabilities. The chart shows the net worth of this innovator in rapid diagnostics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - T2 Biosystems Inc.
T2 Biosystems has developed a technology for rapid sepsis diagnosis. Its balance sheet is its T2Dx diagnostic platform. Its market capitalization reflects the belief that its technology can save lives by allowing doctors to prescribe the right treatment faster. The chart shows its estimated chances of becoming a standard in hospitals.
Market to book capitalization ratio in a market segment - Diagnostic medical equipment
T2 Biosystems has developed a diagnostic platform for the rapid detection of sepsis. Its market valuation chart reflects both the technology's enormous life-saving potential and the significant challenges associated with its widespread commercial adoption in hospitals, which poses a high risk.
Market to book capitalization ratio for the market as a whole
T2 Biosystems, Inc. develops systems for rapid sepsis diagnostics. The company's value is determined by its unique technology and its ability to save lives. This chart shows the premium investors are willing to pay for breakthrough solutions in medical diagnostics aimed at critical conditions.
Debts of the company, segment and market as a whole
TTOO - Company debts T2 Biosystems Inc.
T2 Biosystems, a company that produces rapid sepsis diagnostic systems, is using capital to commercialize its technology. This chart shows how the company is struggling to introduce its innovative but expensive solution into conventional medical practice, requiring significant investments in sales and marketing.
Market segment debts - Diagnostic medical equipment
T2 Biosystems developed a diagnostic platform for the rapid detection of sepsis. Despite its technology, the company has encountered commercialization challenges. This chart reflects its challenging financial situation and demonstrates its reliance on external funding to support its operations and market its products.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio T2 Biosystems Inc.
T2 Biosystems has developed technology for the rapid diagnosis of sepsis and other infections. This chart shows the company's reliance on borrowed funds to produce its diagnostic systems and cartridges, as well as to distribute them to hospitals. It is an indicator of its financial risk in achieving widespread commercial adoption.
Market segment debt to market segment book capitalization - Diagnostic medical equipment
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis and other infections directly from whole blood. The chart shows the sector's debt burden, providing context for assessing how the company is funding the commercialization of its innovative, yet capital-intensive, technology.
Debt to book value of all companies in the market
T2 Biosystems, Inc. is developing a rapid sepsis diagnostic technology, which requires investment in R&D, manufacturing, and commercialization. This chart, showing the overall market debt load, helps understand how the medical diagnostics company is managing its capital as it seeks widespread adoption of its technology in hospitals.
P/E of the company, segment and market as a whole
P/E - T2 Biosystems Inc.
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from whole blood. This chart shows how the market is evaluating its technology. The dynamics reflect the urgent need for rapid sepsis diagnostics, but also the challenges in commercializing new medical tests.
P/E of the market segment - Diagnostic medical equipment
This chart shows the average P/E valuation for the medical diagnostics sector. For T2 Biosystems, with its rapid sepsis detection technology, this is an important benchmark. It helps understand how investors view its potential to change the standard of care compared to larger, more established players in the diagnostics market.
P/E of the market as a whole
T2 Biosystems is a molecular diagnostics company that has developed a technology for rapid detection of sepsis. Its valuation is a bet on its technology. It is not tied to general economic cycles but depends on its ability to demonstrate that its tests save lives and save the healthcare system money.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company T2 Biosystems Inc.
For T2 Biosystems, Inc., a company that produces diagnostic tests for the rapid detection of sepsis, this chart illustrates market expectations for future sales of its panels. It reflects forecasts for growing awareness of sepsis and hospitals' need for rapid diagnostics.
%20P%2FE%20T2%20Biosystems%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-T2-Biosystems-Inc.&v=1772573464492 "Chart of the company's future (projected) P/E T2 Biosystems Inc.")
Future (projected) P/E of the market segment - Diagnostic medical equipment
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly from whole blood. The chart shows forecasts for the medical diagnostics sector. This helps assess the market's confidence in the ability of T2 technology to transform sepsis diagnostic standards and achieve widespread adoption in hospitals.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Diagnostic-medical-equipment&v=1772573464511 "Future (projected) P/E graph of the market segment - Diagnostic medical equipment")
Future (projected) P/E of the market as a whole
T2 Biosystems, Inc. develops diagnostic tests for the rapid detection of sepsis. This is a critical medical need. The company's success depends on the adoption of its technology in hospitals. This market sentiment graph influences the valuation of diagnostic companies solving important but complex medical problems.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772573464576 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit T2 Biosystems Inc.
T2 Biosystems has developed a diagnostic platform for the rapid detection of sepsis-causing pathogens directly from blood. Revenue depends on sales of its systems and cartridges to hospitals. This graph illustrates the complex commercialization of a breakthrough diagnostic technology that can save lives but requires a change in clinical practice.
Profit of companies in the market segment - Diagnostic medical equipment
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly from whole blood. This graph, reflecting the sector's profitability, demonstrates the importance of speed in diagnosing life-threatening conditions. Their technology can save lives by allowing doctors to prescribe the right antibiotic days earlier.
Overall market profit
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from whole blood. This has the potential to save lives. The company's success depends on the implementation of its technology in hospitals. The overall economic stability reflected in the graph allows healthcare facilities to afford such innovative systems.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company T2 Biosystems Inc.
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from whole blood. This has the potential to save lives. This graph reflects analysts' expectations for the implementation of this technology in hospitals, which is key to combating one of the most deadly hospital-acquired infections.
%20profit%20of%20the%20company%20T2%20Biosystems%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-T2-Biosystems-Inc.&v=1772573464875 "Graph of future (projected) profit of the company T2 Biosystems Inc.")
Future (predicted) profit of companies in the market segment - Diagnostic medical equipment
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly from whole blood. The company's growth depends on the adoption of its technology in hospitals. This chart for the medical device sector shows the overall growth expectations for the rapid diagnostics market for critical conditions.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Diagnostic-medical-equipment&v=1772573464998 "Graph of future (predicted) profits of companies in a market segment - Diagnostic medical equipment")
Future (predicted) profit of the market as a whole
T2 Biosystems produces systems for the rapid diagnosis of sepsis and other infections. Demand for its products depends on the adoption of these technologies in hospitals. The overall economic situation, reflected in this graph, impacts healthcare budgets, which may affect the speed of decisions on purchasing new equipment.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772573465027 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - T2 Biosystems Inc.
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from a blood sample. The graph below shows how investors value its revenue, reflecting the critical importance of its technology for saving lives and combating antibiotic resistance in hospitals.
P/S market segment - Diagnostic medical equipment
T2 Biosystems has developed a technology for the rapid diagnosis of sepsis and other dangerous infections directly from a blood sample. The company's revenue depends on sales of its diagnostic panels and devices. This chart reflects the average valuation in the sector, helping to understand how investors view the potential of T2 technology to save lives and reduce healthcare costs.
P/S of the market as a whole
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly from whole blood. This chart, showing the average market revenue estimate, helps understand how investors value the company, whose technology has the potential to save lives by significantly accelerating the diagnosis of this life-threatening condition.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company T2 Biosystems Inc.
T2 Biosystems is a diagnostics company that developed T2MR technology for the rapid detection of sepsis and other infections directly from a blood sample. This chart reflects investor expectations for the future implementation of its diagnostic platform in hospitals to combat one of the most deadly problems in modern medicine.
%20P%2FS%20T2%20Biosystems%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-T2-Biosystems-Inc.&v=1772573465248 "The graph of the company's future (projected) P/S T2 Biosystems Inc.")
Future (projected) P/S of the market segment - Diagnostic medical equipment
T2 Biosystems, Inc. is developing the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly from whole blood. This chart shows the average estimated future sales in the medical diagnostics sector. It helps understand how highly the market values the potential of T2 technology to save lives in sepsis.
%20P%2FS%20market%20segment%20graph%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Diagnostic-medical-equipment&v=1772573465316 "Future (projected) P/S market segment graph - Diagnostic medical equipment")
Future (projected) P/S of the market as a whole
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from whole blood. This graph reflects overall market revenue expectations. The company's technology has the potential to save lives by speeding up diagnosis and appropriate treatment, which is critical in the fight against sepsis.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772573465451 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales T2 Biosystems Inc.
This chart shows sales of T2 Biosystems, a company that produces a diagnostic platform for the rapid detection of pathogens that cause sepsis directly from a blood sample. Revenue is generated from sales of T2Dx devices and test panels. The trend reflects the demand for rapid diagnostics in critical care.
Sales of companies in the market segment - Diagnostic medical equipment
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis pathogens and antibiotic resistance genes directly from whole blood. This graph illustrates the growth of the diagnostics market. The company's technology has the potential to dramatically reduce the time to diagnosis, which is critical for saving lives in sepsis.
Overall market sales
T2 Biosystems develops diagnostic tests for the rapid detection of sepsis and other infections. Demand for its products depends on hospitals' willingness to implement new technologies to improve patient care. This total revenue chart reflects the state of the economy, which impacts healthcare budgets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company T2 Biosystems Inc.
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from a blood sample. Future revenue depends on the adoption of its technology in hospitals to combat this life-threatening condition. The chart below reflects the market forecast.
%20sales%20of%20the%20company%20T2%20Biosystems%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-T2-Biosystems-Inc.&v=1772573465655 "Schedule of future (projected) sales of the company T2 Biosystems Inc.")
Future (projected) sales of companies in the market segment - Diagnostic medical equipment
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly in whole blood, bypassing the culture step. This graph shows the forecast for the entire diagnostic equipment market, where rapid sepsis diagnostics like T2's can save lives.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Diagnostic-medical-equipment&v=1772573465668 "Schedule of future (projected) sales of companies in the market segment - Diagnostic medical equipment")
Future (projected) sales of the market as a whole
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from whole blood. The company's success depends on the adoption of its technology in hospitals. This schedule, reflecting healthcare system budgets, influences clinics' willingness to invest in advanced diagnostic tools to save lives.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772573465834 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality T2 Biosystems Inc.
T2 Biosystems develops diagnostic tests that rapidly detect pathogens that cause sepsis. The company's profitability depends on the implementation of its technology in hospitals, where rapid diagnostic testing can save lives. This graph illustrates the long and arduous road to commercialization of a breakthrough diagnostic technology, which requires changing established clinical practices.
Market segment marginality - Diagnostic medical equipment
T2 Biosystems has developed a technology for the rapid detection of sepsis-causing pathogens directly from blood samples. Profitability depends on the implementation of their T2Dx® diagnostic platform in hospitals to improve patient outcomes. This chart shows the financial results of their efforts to commercialize this vital technology.
Market marginality as a whole
T2 Biosystems is a company that has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from whole blood. This has the potential to save lives. This overall profitability curve isn't as important to them. Their growth depends on hospitals adopting their technology to improve the diagnosis and treatment of this life-threatening condition.
Employees in the company, segment and market as a whole
Number of employees in the company T2 Biosystems Inc.
T2 Biosystems has developed technology for the rapid diagnosis of sepsis and other dangerous infections. Its team consists of engineers, scientists, and commercial personnel. This timeline reflects its efforts to implement its innovative diagnostic platform in hospitals worldwide.
Share of the company's employees T2 Biosystems Inc. within the market segment - Diagnostic medical equipment
T2 Biosystems has developed a technology for the rapid diagnosis of sepsis and other dangerous infections directly from a blood sample. This chart reflects its significant presence in the medical technology niche. It shows the size of the team working to advance this unique platform, which can save lives by significantly reducing the time to diagnosis.
Number of employees in the market segment - Diagnostic medical equipment
T2 Biosystems, Inc. is an in vitro diagnostics company that has developed technology for the rapid detection of sepsis-causing pathogens directly from whole blood. This chart shows employment trends in the medical diagnostics sector. The growth in engineers and sales professionals reflects the urgent need for rapid tests to diagnose life-threatening infections.
Number of employees in the market as a whole
T2 Biosystems develops diagnostic tests for the rapid detection of sepsis and other infections. Demand for its products depends on hospitals' willingness to implement innovative technologies. Overall economic growth, reflected in this chart, supports stable healthcare funding, allowing investment in life-saving solutions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company T2 Biosystems Inc. (TTOO)
T2 Biosystems specializes in the development of diagnostic systems, specifically for ultra-rapid sepsis detection. The business model (T2Dx) involves installing devices (a capital asset) and then selling consumables (test cartridges). The chart shows the market value of this model. The high cost per employee reflects the value of the patented technology and the potential for scaling consumable sales.
%20of%20the%20company%20T2%20Biosystems%20Inc.%20(TTOO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-T2-Biosystems-Inc.-TTOO&v=1772573466318 "Chart of market capitalization per employee (in thousands of dollars) of the company T2 Biosystems Inc. (TTOO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
T2 Biosystems has developed a diagnostic platform that enables rapid detection of sepsis-causing pathogens directly from blood. The company's value lies in its unique technology. This chart shows how the market perceives this technology's potential to save lives and reduce healthcare costs.
%20by%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Diagnostic-medical-equipment&v=1772573466340 "Market capitalization per employee (in thousands of dollars) by market segment - Diagnostic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
T2 Biosystems develops diagnostic tests for the rapid detection of sepsis and other dangerous infections. The chart shows the market's assessment of the diagnostics sector. It reflects how the market views their technology, which can save lives by significantly reducing diagnosis time compared to traditional methods.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772573466380 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company T2 Biosystems Inc. (TTOO)
T2 Biosystems is a molecular diagnostics company specializing in sepsis. Their T2Dx device can detect pathogens (bacteria, fungi) directly in whole blood, bypassing lengthy culture processes. This graph illustrates their struggle for adoption: profit per employee depends on how many hospitals purchase their device and, more importantly, their expensive disposable cartridges.
%20Chart%20T2%20Biosystems%20Inc.%20(TTOO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-T2-Biosystems-Inc.-TTOO&v=1772573466410 "Company Profit Per Employee (in thousands of dollars) Chart T2 Biosystems Inc. (TTOO)")
Profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
T2 Biosystems produces the T2Dx diagnostic platform for the rapid detection of sepsis and other infections. This figure reflects the complexity of commercializing a new diagnostic system and the need to convince hospitals of its clinical and economic value.
%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Diagnostic-medical-equipment&v=1772573466416 "Chart of profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
T2 Biosystems (TTOO) is a medical technology company producing a platform (T2Dx) for rapid sepsis diagnostics. It's an R&D and "razor blade business." This chart likely shows the loss per employee, reflecting the difficulty of selling their expensive devices (razors) and cartridges (razor blades) to hospitals.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772573466489 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee T2 Biosystems Inc. (TTOO)
T2 Biosystems has developed the T2Dx diagnostic platform, which enables rapid detection of sepsis-causing pathogens directly from whole blood. This chart demonstrates the commercial success of its technology. The increase in revenue per employee demonstrates the adoption of its system in hospitals, helping save lives through rapid diagnostics.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-T2-Biosystems-Inc.-TTOO&v=1772573466613 "Sales chart per company employee T2 Biosystems Inc. (TTOO)")
Sales per employee in the market segment - Diagnostic medical equipment
T2 Biosystems (TTOO) produces a diagnostic platform (T2Dx) that can rapidly identify pathogens that cause sepsis directly from whole blood. This is critical to saving lives. This graph shows the revenue (from sales of devices and test cartridges) generated by each employee (engineer, salesperson).
Sales per employee for the market as a whole
T2 Biosystems (TTOO) develops diagnostic solutions for the rapid detection of sepsis and Lyme disease. Its business model is a "razor and blade": the company installs its devices (T2Dx) in hospitals to generate recurring revenue from the sale of high-margin cartridges. This chart shows how successfully the company is growing its consumable sales.
Short shares by company, segment and market as a whole
Shares shorted by company T2 Biosystems Inc. (TTOO)
T2 Biosystems is developing a diagnostic platform for rapid sepsis detection. The bearish sentiment expressed by this chart is a bet that its technology, despite its importance, will not be adopted by hospitals due to its cost and complexity of implementation.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-T2-Biosystems-Inc.-TTOO&v=1772573466827 "Short Shares Chart for the Company T2 Biosystems Inc. (TTOO)")
Shares shorted by market segment - Diagnostic medical equipment
T2 Biosystems (TTOO) is racing against time, developing platforms for rapid diagnostics of sepsis and Lyme disease, where T2MR allows for pathogen detection without lengthy blood cultures. This chart reflects the overall investor skepticism toward the entire medical diagnostics sector. The rising price is a bet that the industry will face reimbursement challenges or intense competition, slowing the adoption of innovations.
Shares shorted by the overall market
T2 Biosystems offers a platform for rapid sepsis diagnostics. Despite its important mission, the company is a microcap, chronically burning cash. This chart illustrates the general fear. When investors are afraid, they sell off shares of companies on the brink of survival. They fear that TTOO will be unable to refinance and will go bankrupt.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator T2 Biosystems Inc. (TTOO)
T2 Biosystems (TTOO) produces the T2Dx diagnostic system, which can quickly detect sepsis and other infections directly from a blood sample. This is a critical technology. This oscillator measures the strength of speculative moves. It shows when stocks are "overheated" (above 70) on FDA approval news or "oversold" (below 30) due to selling pressure.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-T2-Biosystems-Inc.-TTOO&v=1772573467069 "RSI 14 indicator chart for the company's stock T2 Biosystems Inc. (TTOO)")
RSI 14 Market Segment - Diagnostic medical equipment
T2 Biosystems is a "magnet" against *sepsis*. Their *diagnostic* platform (T2Dx) uses *magnetic resonance* (T2MR) to *ultra-fast* (hours) detect *pathogens* (bacteria, fungi) *directly in the blood*. The "Diagnostic medical equipment" sector (medtech/diagnostics) thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps understand: is TTOO's growth a niche or a general hype?
RSI 14 for the overall market
T2 Biosystems (TTOO) is a cash-burning biotech. This chart is its lifeline. During periods of market euphoria, investors are willing to "buy the dream" and fund unprofitable R&D projects. During moments of panic, the cash tap is turned off, and investors demand profits rather than promises, putting TTOO at risk of survival.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TTOO (T2 Biosystems Inc.)
T2 Biosystems is the company that developed the T2Dx technology for rapid detection of sepsis (bacteria and fungi) directly in blood, bypassing culture. This chart shows the analysts' average 12-month forecast. It reflects their view on whether hospitals will be able to widely implement this expensive but lifesaving test.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TTOO-T2-Biosystems-Inc.&v=1772573467209 "A chart showing analyst consensus forecasts for the expected stock price. TTOO (T2 Biosystems Inc.)")
The difference between the consensus estimate and the actual stock price TTOO (T2 Biosystems Inc.)
T2 Biosystems (TTOO) is a "first aid" for sepsis. Their diagnostic platform (T2Dx) promises to *quickly* (within hours) detect dangerous pathogens (fungi, bacteria) directly in the blood. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the implementation of this technology in hospitals.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TTOO-T2-Biosystems-Inc.&v=1772573467242 "A chart showing the difference between the consensus forecast and the actual stock price. TTOO (T2 Biosystems Inc.)")
Analyst consensus forecast for stock prices by market segment - Diagnostic medical equipment
T2 Biosystems (TTOO) is a "rapid aid" in diagnostics. The company produces a system (T2Dx) that can detect sepsis (blood poisoning) in hours, not days. This chart shows general expectations for the diagnostic equipment sector. It reflects whether experts believe hospitals are willing to pay for "ultra-fast" diagnostics.
Analysts' consensus forecast for the overall market share price
T2 Biosystems (TTOO) is a sepsis hunter. Their T2Dx diagnostic platform is the only one that can detect deadly pathogens *directly* in the blood in 3-5 hours, not days. This saves lives. This chart shows the overall risk appetite. It reflects the degree to which investors believe conservative hospitals are willing to spend money (CapEx) on implementing new technologies.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index T2 Biosystems Inc.
T2 Biosystems specializes in the rapid diagnosis of life-threatening infections, including sepsis, using its T2MR magnetic resonance technology. Success depends on the deployment of their devices in hospitals. This chart is an integrated assessment reflecting the speed of commercialization, growth in consumables (cartridge) sales, and market acceptance of their technology in the fight against sepsis.
AKIMA Market Segment Index - Diagnostic medical equipment
T2 Biosystems (TTOO) is a diagnostic medical device for critical situations. Their T2Dx platform can detect sepsis and superbugs directly from blood samples in hours, not days. This chart compares their composite index to the medtech sector average.
The AKIM Index for the overall market
T2 Biosystems is a diagnostic company offering rapid tests for detecting sepsis pathogens directly from blood. This chart, reflecting the market average, is a backdrop. It helps assess how T2 Biosystems, which is struggling to gain acceptance for its technology, compares to overall macroeconomic trends.
